Treatment Naïve, Chronic HCV

Peginterferon alfa-2b + Weight-based Ribavirin in HCV GT 2,3

Peginterferon alfa-2b + Ribavirin for GT 2 or 3
Study Design

- **Study**
  - Single arm, open-label, historical-control, phase 4 study
  - Conducted in 39 centers in Europe

- **Subjects**
  - N = 224 with chronic hepatitis C enrolled (223 treated)
  - Treatment naïve adult patients with genotype 2 or 3 HCV

- **Regimens**
  - Peginterferon alfa-2b: 1.5 μg/kg/wk + Ribavirin*: 800-1400 mg/d x 24 wks

- **Primary Endpoint**
  - Undetectable serum HCV RNA at end of treatment (ETR)
  - Undetectable serum HCV RNA 24 wks after cessation of treatment (SVR)

*Ribavirin dosing: <65 kg = 800 mg/d; 65-85 kg = 1000 mg/d; >85-105 kg = 1200 mg/d; >105 kg = 1400 mg/d

Peginterferon alfa-2b + RBV for 12 or 24 Weeks in GT 2 or 3

Treatment Duration and Ribavirin Dose

Week 0 → 24 → 48

N = 224

Peginterferon alfa-2a + Ribavirin

SVR24

Drug Dosing

Peginterferon alfa-2b: 1.5 µg/kg 1x/week
Ribavirin (divided bid): 800-1400 mg/day
Ribavirin dosing: <65 kg = 800 mg/d; 65-85 kg = 1000 mg/d; >85-105 kg = 1200 mg/d; >105 kg = 1400 mg/d

Peginterferon alfa-2b + Ribavirin for GT 2 or 3

Results

SVR24 Rates, by Genotype

<table>
<thead>
<tr>
<th></th>
<th>Patients with SVR 24 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>81/224 (36%)</td>
</tr>
<tr>
<td>Genotype 2</td>
<td>93/42 (22%)</td>
</tr>
<tr>
<td>Genotype 3</td>
<td>79/182 (43%)</td>
</tr>
</tbody>
</table>

Conclusions: “Treatment for 24 weeks with peginterferon alfa-2b and ribavirin is sufficient in HCV 2 or 3 infected patients. The lower SVR in patients infected with HCV-3 compared with HCV-2 infected patients may be related to higher levels of steatosis in this population.”

This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

http://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.